1. Biosimilars—why terminology matters;Weise;Nat Biotech,2011
2. Follow-on biologics: Data exclusivity and the balance between innovation and competition;Grabowski;Nat Rev,2008
3. An Unofficial Legislative History of the Biologics Price Competition and Innovation Act of 2009;Carver;FDLI,2010
4. Data exclusivity for biologics;Grabowski;Nat Rev,2011
5. Pharmaceutical evaluation of biosimilars: Important differences from generic low-molecular-weight pharmaceuticals;Crommelin;Eur J Hosp Pharm Sci,2005